CMS Denies Lilly’s Request For Broad Medicare Coverage Of Amyvid In Draft Memo
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare would only cover beta amyloid positron emission tomography in diagnosing dementia, relying on Lilly’s imaging agent, as part of a clinical trial, according to a proposed decision memo.